Real-world efficacy and toxicity of ipilimumab and nivolumab as first line treatment of metastatic renal cell carcinoma (mRCC) in a subpopulation of elderly and poor performance status patients.Ana-Alicia Beltran-Bless, Christina M. Canil, Nazanin Fallah‐Rad et al.|Journal of Clinical Oncology|2024Cited by 2
Real-world treatment outcomes in patients with advanced renal cell carcinoma who receive axitinib plus pembrolizumab in the first-line setting in Canadian cancer centers.Carissa Beaulieu, Naveen S. Basappa, Sunita Ghosh et al.|Journal of Clinical Oncology|2024Cited by 1
Association between abnormal IMDC laboratory criteria after surgery and cancer-specific and overall survival in non-metastatic renal cell carcinoma: Potential biomarkers for adjuvant therapy patient selection.Caio Vinícius Suartz, Frédéric Pouliot, Rodney H. Breau et al.|Journal of Clinical Oncology|2025Cited by 0
Outcomes of delayed cytoreductive nephrectomy in patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint inhibitor therapy.Mohamed Soufi, Jeffrey Graham, Sunita Ghosh et al.|Journal of Clinical Oncology|2026Cited by 0